Last reviewed · How we verify
Polysporin Triple
Polysporin Triple is a topical antibiotic combination that kills bacteria by inhibiting protein synthesis and cell wall integrity through multiple mechanisms.
Polysporin Triple is a topical antibiotic combination that kills bacteria by inhibiting protein synthesis and cell wall integrity through multiple mechanisms. Used for Prevention of infection in minor cuts, scrapes, and burns, Topical treatment of minor bacterial skin infections.
At a glance
| Generic name | Polysporin Triple |
|---|---|
| Sponsor | University Health Network, Toronto |
| Drug class | Topical antibiotic combination |
| Target | Bacterial cell wall (bacitracin), bacterial ribosome (neomycin), bacterial cell membrane (polymyxin B) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infection |
| Phase | FDA-approved |
Mechanism of action
Polysporin Triple contains bacitracin, neomycin, and polymyxin B, three antibiotics with complementary mechanisms of action. Bacitracin inhibits bacterial cell wall synthesis, neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit, and polymyxin B disrupts bacterial cell membranes. This triple combination provides broad-spectrum coverage against common skin pathogens.
Approved indications
- Prevention of infection in minor cuts, scrapes, and burns
- Topical treatment of minor bacterial skin infections
Common side effects
- Local skin irritation or rash
- Allergic contact dermatitis
- Sensitization to neomycin
Key clinical trials
- Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections (NA)
- Use of Ointments in Prevention of Catheter Related Infections in PD (PHASE4)
- Hemodialysis Infection Prevention Using Polysporin Ointment With Shower Technique in Satellite Centres Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polysporin Triple CI brief — competitive landscape report
- Polysporin Triple updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI